Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

[1]  J. Flynn,et al.  Profound neurological injury in a patient with atypical hemolytic uremic syndrome , 2013, Annals of Hematology.

[2]  A. Bagga,et al.  Peripheral Gangrene in Children With Atypical Hemolytic Uremic Syndrome , 2013, Pediatrics.

[3]  D. Ricklin,et al.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. , 2012, Immunobiology.

[4]  B. Acar,et al.  Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation , 2012, Pediatric Nephrology.

[5]  V. Frémeaux-Bacchi,et al.  Atypical hemolytic uremic syndrome , 2011, Orphanet journal of rare diseases.

[6]  V. Savell,et al.  Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation , 2011, Pediatric Nephrology.

[7]  B. Hurault de Ligny,et al.  Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. , 2010, Transplantation proceedings.

[8]  Amy E. Weaver,et al.  Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome , 2010, Human mutation.

[9]  B. Nilsson,et al.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). , 2008, Molecular immunology.

[10]  B. Paul Morgan,et al.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome , 2007, Proceedings of the National Academy of Sciences.

[11]  A. Duzova,et al.  Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab , 2012, Pediatric Nephrology.

[12]  K. Joiner.  Complement evasion by bacteria and parasites. , 1988, Annual review of microbiology.